MediWound to launch Phase III trial for venous leg ulcers
MediWound initiates Phase III trial for venous leg ulcer treatment. Success in trials could significantly boost MDWD's market position.
View signal analysisCompany intelligence
MDWD
MediWound Ltd. · NASDAQ · Healthcare
Price$13.34-0.97% · −$0.13
Market cap171.36MEquity value
P / E-5.9Trailing ratio
Volume29.82KLatest session
Market data
TradingViewMDWD price chart
Related signals
1 min delayedLatest MDWD price-moving signals
Browse public MDWD signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Research